Vivos Q2 Revenue Jumps 35% to $5.2M, But Cash Drops to $1.8M and Equity Deficit Widens
VVOS sits 27% above its 52-week low of $0.271.
Summary
Vivos Therapeutics reported Q2 2026 revenue of $5.2 million, up 35% year-over-year, with gross margin improving to 57%. The company posted an operating loss of $4.9 million, flat versus last year, and cash fell to $1.8 million from $2.0 million at year-end. Stockholders' equity deficit widened to $3.8 million from $1.5 million. The company highlighted increasing patient demand and revenue growth in its Nevada treatment centers and pediatric program, but the balance sheet remains precarious with a going concern warning already in place. Management will host a conference call today at 5:00 pm ET to discuss strategic initiatives and near-term cash burn.
At the time of this announcement, VVOS was trading at $0.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.8M. The 52-week trading range was $0.27 to $5.12. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.